← Markets Angelini Ventures and EIB Co-lead $58 Million Series A Financing in Rouge Therapeutics to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
globenewswire_country_it · Rouge Therapeutics ·
Marks the fourth investment completed under Angelini Ventures’ €150 million co-investment partnership with the European Investment Bank in less than 12 months